Intended for US audiences only.


Baylor College of Medicine website. https://www.bcm.edu/research/medical-genetics-labs/test_detail.cfm?testcode=32750&show=1. Accessed April 23, 2018.

Byers PH, Belmont J, Black J, et al. Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):40-47.

Christian Hendrickz. Rare Disease Impact Report: Insights from patients and the medical community. http://www.academia.edu/18842593/Rare_Disease_Impact_Report_Insights_from_patients_and_the_medical_community. Accessed January 5, 2018.

Chu LC, Johnson PT, Dietz HC, et al. Vascular complications of Ehlers-Danlos syndrome: CT findings. AJR Am J Roentgenol. 2012;198(2):482-487.

Data on File - Acer Therapeutics

Frank M, Albuisson J, Ranque B, et al. The types of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndrome. Eur J Hum Genet. 2015;23(12):1657-1664.

MedlinePlus. U.S. National Library of Medicine website https://medlineplus.gov/mplusdictionary.html. Updated April 18, 2012. Accessed January 5, 2018.

Nawarskas JJ, Cheng-Lai A, Frishman WH. Celiprolol – a unique selective adrenoceptor modulator. Cardiol Rev. 2017;25(5):247-253.

Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342(10):673-680.

Pepin MG, Schwarze U, Rice KM, Liu M, Leistritz D, Byers PH. Survival is affected by mutation type and molecular mechanism in vascular Ehlers-Danlos syndrome (EDS type IV). Genet Med. 2014;16(12):881-888.

Pepin MG, Murray ML, Byers PH. Vascular Ehlers-Danlos Syndrome. GeneReviews®. Seattle (WA): University of Washington, Seattle; September 1999, last updated November 2015.

Voermans NC, Knoop H, Bleijenberg G, van Engelen BG. Pain in Ehlers-Danlos Syndrome is common, severe, and associated with functional impairment. J Pain Symptom Manage. 2010;40(3):374.


Sign up

Register below if you would like to receive the latest vEDS news, tips, and information from Acer Therapeutics.

How are you affected by vEDS?

The personally identifiable information you provide to Acer Therapeutics will only be used for purposes for which you have provided it. Specifically, the contact information you provided (including but not limited to name, email, and ZIP code) will be used to contact you about the subjects you agreed to in the check boxes above. When you submit personally identifiable information, you consent to its disclosure and use for the above purposes. We may share your information with our partners who facilitate the delivery of this information.

ERROR: There was a problem with your submission. Please fill out the highlighted fields.

Thank You

You have already signed up!

Thank You

You have already submitted your tapestry! Click here to sign up!

Thanks for signing up!